Cargando…

The effect of molnupiravir on post-acute outcome of COVID-19 survivors

Detalles Bibliográficos
Autores principales:	Hsu, Wan-Hsuan, Shiau, Bo-Wen, Tsai, Ya-Wen, Wu, Jheng-Yan, Liu, Ting-Hui, Chuang, Min-Hsiang, Lai, Chih-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029330/ https://www.ncbi.nlm.nih.gov/pubmed/36958635 http://dx.doi.org/10.1016/j.jinf.2023.03.016

Ejemplares similares

Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 for patients with dementia
por: Liu, Ting-Hui, et al.
Publicado: (2023)

Comparison of post-acute sequelae following hospitalization for COVID-19 and influenza
por: Liu, Ting-Hui, et al.
Publicado: (2023)

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients
por: Liu, Ting-Hui, et al.
Publicado: (2023)

The effect of zinc on the outcome of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
por: Wu, Jheng-Yan, et al.
Publicado: (2023)

The risk of methicillin-resistant Staphylococcus aureus infection following COVID-19 and influenza: A retrospective cohort study from the TriNetX network
por: Tsai, Ya-Wen, et al.
Publicado: (2023)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials
por: Wu, Jheng-Yan, et al.
Publicado: (2023)

Correction to: Efficacy and safety of adjunctive corticosteroids in the treatment of severe community‑acquired pneumonia: a systematic review and meta‑analysis of randomized controlled trials
por: Wu, Jheng‑Yan, et al.
Publicado: (2023)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

Complicated Pandemic (H1N1) 2009 during Pregnancy, Taiwan
por: Huang, Wan-Ting, et al.
Publicado: (2011)

The association between corticosteroids and aspergillosis among COVID-19 patients
por: Chang, Yi-Hsin, et al.
Publicado: (2023)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Tailored Post-Acute Care Coordination for Survivors of Moderate to Severe COVID-19 Infection
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2022)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
por: Xie, Yan, et al.
Publicado: (2023)

In vitro and in vivo efficacy of Molnupiravir against Zika virus infections
por: Wang, Zhuang, et al.
Publicado: (2023)

Successful Hematopoietic Stem Cell Transplantation from a Donor Sibling Infected with SARS-CoV-2 Using Molnupiravir Prophylaxis
por: Mandacı Şanlı, Neslihan, et al.
Publicado: (2023)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing hospitalization
por: Scioscia, Giulia, et al.
Publicado: (2022)

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
por: Clark, Nicole F., et al.
Publicado: (2022)

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
por: Menéndez-Arias, Luis
Publicado: (2021)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
por: Lee, Ching-Chi, et al.
Publicado: (2021)

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden
por: Juliusson, G, et al.
Publicado: (2017)

Is the number of long-term post-COVID symptoms relevant in hospitalized COVID-19 survivors?
por: Fernández-de-las-Peñas, César, et al.
Publicado: (2022)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Lomustine induced acute pulmonary toxicity in a pediatric medulloblastoma survivor
por: Radhakrishnan, Venkatraman, et al.
Publicado: (2017)

Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat
por: Chang, Chun-Hao, et al.
Publicado: (2023)

Victims or survivors?
por: Alachkar, Mustafa
Publicado: (2016)

Early Comprehensive Kidney Care in Dialysis-Requiring Acute Kidney Injury Survivors: A Populational Study
por: Wu, Chun-Yi, et al.
Publicado: (2022)

ADCY5-related dyskinesia: a case report
por: Chen, Shih-Ying, et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Effects of the Hospital Gradation System on Patient Behavior and Satisfaction: An Investigation of Dental Health Care
por: CHANG, Wen-Jen, et al.
Publicado: (2015)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier
por: Chang, Chun-Hao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p82kktm89fgojuu1lipf74g07g